In silico targeting SARS-CoV-2 spike protein and main protease by biochemical compounds
- 22 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Biologia
- Vol. 76 (11), 3547-3565
- https://doi.org/10.1007/s11756-021-00881-z
Abstract
Since there is no general agreement on drug treatment of SARS-CoV-2, the search for a new drug capable of treating COVID-19 is of utmost priority. This study aims to dereplicate the chemical compounds of the methanol extract of Salvia officinalis and Artemisia dracunculus, and assay the inhibitory effect of these compounds as well as the previously dereplicated components of Zingiber officinale against SARS-CoV-2 in an in-silico study. A molecular networking (MN) technique was applied to find the chemical constituents of the extracts. Docking analysis was also used to find the binding affinity of dereplicated components from S. officinalis, A. dracunculus, and Z. officinale to COV-2-SP and Mpro. 57 compounds were dereplicated from the MeOH extracts of S. officinalis and A. dracunculus which include the class of polyphenols, flavonoids, coumarins, phenylpropanoids, anthocyanins, and dihydrochalcones. Molecular docking analysis indicated a high affinity of about 27 compounds from three mentioned plants against studied targets. kaempferol 3-O-rutinoside, neodiosmin, and querciturone with docking score values of -10.575, -10.208, and − 9.904 Kcal/mol and ki values of 0.016606, 0.030921, and 0.051749, respectively were found to have the highest affinities against COV-2-SP. 2-phenylethyl beta-primeveroside, curcumin PE, and kaempferol 3-O-rutinoside also indicated the highest affinity against Mpro with docking scores of -10.34, -10.126 and − 9.705 and ki values of 0.024726, 0.035529, and 0.072494, respectively. MN can be successfully used for the dereplication of metabolites from plant extracts. In addition, the in-silico binding energies introduced several inhibitors from Z. officinale, S. officinalis, and A. dracunculus for the treatment of SARS-CoV-2 disease.Keywords
This publication has 56 references indexed in Scilit:
- Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastorisBiotechnology Letters, 2012
- Emodin inhibits current through SARS-associated coronavirus 3a proteinAntiviral Research, 2011
- Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibitionBioorganic & Medicinal Chemistry, 2010
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interactionAntiviral Research, 2007
- Water and methanolic extracts of Salvia officinalis protect HepG2 cells from t-BHP induced oxidative damageChemico-Biological Interactions, 2007
- Virus entry: molecular mechanisms and biomedical applicationsNature Reviews Microbiology, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core ComplexJournal of Virology, 2003
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003